With so much hype and snake-oil sales tactics surrounding AI/data-driven approaches in drug discovery it's great to read this very pragmatic article from Ben Sidders at Biorelate Ltd. outlining how to maximise its impact in R&D organisations. Well worth a read.
AI/data-driven drug discovery is starting to evolve at an encouraging rate now. But the technology’s positive impact will depend on how well the technology, and the insights it elicits, are embedded into R&D, says Biorelate Ltd.’s Chief Scientific Officer, Dr Ben Sidders here in the Journal for Clinical Studies >> https://lnkd.in/e5Pb9NUJ #drugdiscovery #AI #lifesciences
Ian Waddell
2mo
Thanks for posting Phil, ceratinly an article that is relevant to everyone at Cumulus Oncology
Clare Wareing
2mo
Thanks for sharing this article Phil Chapman. Always good to get a balanced perspective 👍
Thanks Phil, good read
Interesting, not only for current relevance, but how it echoes the "early days" of DNA sequence analysis caveats. Small datasets, still-unstructured literature. His statement: "Predicting that a drug might work in a new indication is valuable, but it is not the same as explaining why the drug will work in that indication" reminded me of the "Whisky cures cancer" joke in an old YouTube AI parody (cannot find it now, there's too much chaff)